SG/CALL/NOVO-NORDISK B/1150/0.1/20.06.25 | Real-time Boerse Frankfurt Warrants 01:30:25 03/06/2024 pm IST | ||
| 0.87 EUR | -3.33% |
|
| 1 month | -10.89% | ||
| 3 months | +11.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.87 | -3.33% |
| 31/24/31 | 0.9 | +4.65% |
| 30/24/30 | 0.86 | +1.18% |
| 29/24/29 | 0.85 | -7.61% |
| 28/24/28 | 0.92 | -9.80% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 01:30 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CVV |
| ISIN | DE000SU9CVV2 |
| Date issued | 14/02/2024 |
| Strike | 1,150 kr |
| Maturity | 20/06/2025 (383 Days) |
| Parity | 10 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.39 € |
|---|---|
| Lowest since issue | 0.71 € |
| Spread | 0.02 € |
| Spread % | 2.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
